What Are Requip and Requip XL?
Requip (ropinirole immediate-release) and Requip XL (ropinirole extended-release) both treat Parkinson's disease and restless legs syndrome (RLS) by mimicking dopamine in the brain. The main difference is in their release mechanism: Requip releases the drug quickly for immediate effects, while Requip XL releases it slowly over 24 hours.[1]
Key Formulation Differences
- Release Profile: Requip requires multiple daily doses (typically 3 times a day). Requip XL is taken once daily, using a matrix system that gradually erodes to release ropinirole.[1][2]
- Dosage Forms: Requip comes in 0.25 mg, 0.5 mg, 1 mg, 2 mg, and 5 mg tablets. Requip XL offers 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg extended-release tablets.[1]
- Switching Between Them: Patients can convert directly using equivalent total daily doses, but doctors adjust based on response. For example, 3 mg/day immediate-release equals about 2 mg/day XL.[2]
Dosing Schedules Compared
| Condition | Requip (Immediate-Release) Dosing | Requip XL (Extended-Release) Dosing |
|--------------------|-----------------------------------|-------------------------------------|
| Parkinson's | 3x daily, titrated up to 24 mg/day | Once daily, up to 24 mg/day |
| Restless Legs Syndrome | Once daily (1-2 hours before bedtime), up to 4 mg | Once daily (1-3 hours before bedtime), up to 4 mg[1][2] |
Requip XL maintains steadier drug levels, potentially reducing "on-off" fluctuations in Parkinson's symptoms.[3]
Effectiveness and Clinical Data
Studies show similar efficacy for both in controlling symptoms, but Requip XL improves compliance with once-daily dosing and may enhance sleep quality in RLS patients due to consistent coverage. A head-to-head trial found non-inferiority for motor control in early Parkinson's.[3][4]
Common Side Effects and Patient Experiences
Both share risks like nausea, dizziness, somnolence, and hallucinations. Requip XL reports slightly lower peak-related nausea from smoother release. Patients often prefer XL for convenience, though some note initial adjustment issues.[1][4]
Availability, Patents, and Generics
Requip launched in 1997; generics available since 2008. Requip XL launched in 2008; its patents expired around 2018-2020, with generics now marketed (e.g., ropinirole ER from Mylan, Teva).[1] Check DrugPatentWatch.com for exact expiry details and ANDA filings on ropinirole extended-release.
[1]: Requip XL Prescribing Information, GSK.
[2]: Requip Prescribing Information, GSK.
[3]: Neurology, 2009;72(6):441-8 (Hauser et al. study).
[4]: FDA Label Approvals, Requip XL.